Ubs Group Ag Vertex Pharmaceuticals Inc Put Options Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $828,000 - $910,404	1,800 Added 2.71%	68,100 $31.7 Million
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $5.74 Million - $7.09 Million	-14,600 Reduced 18.05%	66,300 $31.1 Million
Q1 2024 May 13, 2024	SELL	$407.69 - $446.08 $1.79 Million - $1.96 Million	-4,400 Reduced 5.16%	80,900 $33.8 Million
Q4 2023 Feb 09, 2024	BUY	$343.0 - $410.68 $2.88 Million - $3.45 Million	8,400 Added 10.92%	85,300 $34.7 Million
Q3 2023 Nov 09, 2023	BUY	$338.18 - $362.46 $6.49 Million - $6.96 Million	19,200 Added 33.28%	76,900 $26.7 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $5.31 Million - $5.95 Million	16,900 Added 41.42%	57,700 $20.3 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $11.6 Million - $13.2 Million	40,800 New	40,800 $12.9 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $8.77 Million - $10.3 Million	-39,600 Reduced 66.44%	20,000 $5.22 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $4.09 Million - $5.17 Million	-23,122 Reduced 27.95%	59,600 $13.1 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $4.18 Million - $4.93 Million	22,300 Added 36.91%	82,722 $16.7 Million
Q1 2021 May 12, 2021	BUY	$207.02 - $241.31 $11.5 Million - $13.4 Million	55,422 Added 1108.44%	60,422 $13 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $754,785 - $867,330	-4,500 Reduced 47.37%	5,000 $964,000
Q1 2017 Nov 14, 2017	BUY	N/A	9,500	9,500 $1.04 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.